Considering the epidermal growth factor receptor (EGFR) gene amplification and protein overexpression in GBM cells, the cyclophosphamide loaded SLNs were superficially modulated with anti-EGFR antibodies [77,78]. The gene discussed is EGFR; the disease is glioblastoma.